University of Michigan
Dr. Koschmann is a Pediatric Neuro-Oncologist in the Department of Pediatrics and a Principal Investigator of an independent translational Pediatric Neuro-Oncology laboratory. His work in the clinic and lab complement and drive each other, resulting in a clear goal to improve therapies for children with brain tumors. He has engaged in research and the clinical care of pediatric brain tumor patients at both Seattle Children’s Hospital and the University of Michigan’s Mott Children’s Hospital. The Koschmann laboratory is exploring the molecular mechanisms by which recurrent mutations in pediatric high-grade glioma (HGG), including glioblastoma (GBM), anaplastic astrocytoma (AA) and diffuse intrinsic pontine glioma (DIPG) promotes tumor formation and affect treatment response.
Dr. Koschmann has applied this precision medicine approach in translational and clinical work in Pediatric Neuro-Oncology. Along with researchers and colleagues from multiple clinical divisions at the University of Michigan and other institutions, he developed and co-facilitate the UM CNS Precision Medicine conference. In this multi-disciplinary and multi-institutional conference, molecular results are incorporated from pediatric brain tumor patients (paired tumor/germline sequencing results and pre-clinical cell culture treatment studies) into their treatment. Dr. Koschmann has established new algorithms and are in the process of developing multiple clinical trials incorporating the use of molecularly targeted therapy for pediatric patients with brain tumors. He will serve as PI for these trials and their biologic correlative research.
Michigan Medicine C.S. Mott Children’s Hospital
MET Alterations in DMGs
Recent work has pointed to dysregulation of a cellular process called the mesenchymal-epithelial transition (MET) as a driver for diffuse midline gliomas (DMGs). This project will further explore this dysregulation in an effort to identify new therapeutic targets for DMGs.
Regional Response to ONC201 in Pediatric High-Grade Glioma
New targeted therapies are needed to address pediatric high grade gliomas with H3K27M mutations. The Children’s Brain Tumor Network will provide researchers with pHGG cell lines and data to pursue the development of therapeutics.
Comparison of Fusion Calling Platforms in Pediatric DIPG and High‐grade Glioma
Targeted therapeutic options are limited for patients with diffuse intrinsic pontine glioma (DIPG). Researchers will perform state of the art analysis on data from the Pediatric Brain Tumor Atlas in an effort to identify new therapies for patients with DIPG.
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with